About

James M. Hindman has served on Accuray's Board since September 2019 and chairs the Audit Committee. He held various positions at Allergan from 1984 to 2015, most recently as Executive Vice President, Finance and Business Development, and Chief Financial Officer, and earlier as Senior Vice President of Treasury, Risk and Investor Relations. He currently serves on the board of Aatru Medical and has served on the boards of Millendo Therapeutics, Sienna Biopharmaceuticals, Urovant Sciences and Amolyt Pharma. He holds a B.S. in Accounting from Loyola Marymount University and an MBA from Pepperdine University, and is a California CPA (inactive).

Roles

Accuray Inc.
Director (Chair, Audit Committee) · Current role
September 2019–present
Allergan, Inc.
Executive Vice President, Finance and Business Development, and Chief Financial Officer
August 2014 - March 2015
Allergan, Inc.
Senior Vice President of Treasury, Risk and Investor Relations
March 2002 - August 2014
Allergan, Inc.
Various finance roles
1984 - 2002

External Roles

Aatru Medical, LLC
Director
present
Millendo Therapeutics, Inc.
Director
2016 - 2021
Urovant Sciences, Inc.
Director
2020 - 2023
Amolyt Pharma SAS
Director
2021 - 2024

Director Compensation

FY 2025
Fees earned or paid in cash
$82,500
ComponentAnnual cash retainer plus Audit Committee chair retainer earned in fiscal 2025
Stock awards
$126,225
ComponentAnnual RSU grant (11/29/24), ASC 718 grant-date fair value
Total
$208,725

Also at Accuray Inc.

Related

See how VectorShift works for your firm

Request Demo